In vivo study of breast carcinoma radiosensitization by targeting eIF4E

Biochemical and Biophysical Research Communications

Volumn 423, Issue 4, 2012, Pages 878-883

  Yang, Hua ^a   Li, Li Wen ^a,b   Shi, Mei ^a   Wang, Jian Hua ^a   Xiao, Feng ^a   Zhou, Bin ^a   Diao, Li Qiong ^a   Long, Xiao Li ^a   Liu, Xiao Li ^a   Xu, Lin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

Author keywords

Breast cancer; EIF4E; PSecX t4EBP1; Radiosensitization; Xenograft

Indexed keywords

INITIATION FACTOR 4E; PROTEIN INHIBITOR; PSECX T4EBP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GENE THERAPY; GENETIC VECTORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; PHOSPHOPROTEINS; RADIATION TOLERANCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EUKARYOTA; MUS;

EID: 84863854645     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.064     Document Type: Article

References (40)

1. Parkin D.M., Fernandez L.M. Use of statistics to assess the global burden of breast cancer. Breast J. 2006, 12(Suppl 1):S70-S80.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
3. Arthur D.W., Morris M.M., Vicini F.A. Breast cancer: new radiation treatment options. Oncology (Williston Park) 2004, 18:1621-1629. 1629-1630, 1636-1638.
4. Violet J.A., Harmer C. Breast cancer: improving outcome following adjuvant radiotherapy. Br. J. Radiol. 2004, 77:811-820.
5. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., Amorino G., Lin P.S. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 2003, 22:5855-5865.
6. Jameel J.K., Rao V.S., Cawkwell L., Drew P.J. Radioresistance in carcinoma of the breast. Breast 2004, 13:452-460.
7. Lawrence J.J., Abraham R.T. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem. Sci. 1997, 22:345-349.
8. Gingras A.C., Raught B., Sonenberg N. EIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 1999, 68:913-963.
9. Magagnin M.G., van den Beucken T., Sergeant K., et al. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics 2008, 8:1019-1028.
10. Clemens M.J., Bushell M., Jeffrey I.W., Pain V.M., Morley S.J. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ. 2000, 7:603-615.
11. Tan A., Bitterman P., Sonenberg N., Peterson M., Polunovsky V. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000, 19:1437-1447.
12. Li S., Sonenberg N., Gingras A.C., et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell Biol. 2002, 22:2853-2861.
13. Nathan C.O., Liu L., Li B.D., Abreo F.W., Nandy I., De Benedetti A. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997, 15:579-584.
14. Rosenwald I.B., Chen J.J., Wang S., Savas L., London I.M., Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999, 18:2507-2517.
15. Wang S., Rosenwald I.B., Hutzler M.J., et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am. J. Pathol. 1999, 155:247-255.
16. Lee J.W., Choi J.J., Lee K.M., et al. EIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum. Pathol. 2005, 36:1197-1203.
17. Byrnes K., White S., Chu Q., et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann. Surg. 2006, 243:684-690. 691-692.
18. Nathan C.O., Carter P., Liu L., et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997, 15:1087-1094.
19. Rousseau D., Kaspar R., Rosenwald I., Gehrke L., Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. USA 1996, 93:1065-1070.
20. Ruggero D., Montanaro L., Ma L., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 2004, 10:484-486.
21. Lazaris-Karatzas A., Montine K.S., Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990, 345:544-547.
22. Zimmer S.G., DeBenedetti A., Graff J.R. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 2000, 20:1343-1351.
23. Kerekatte V., Smiley K., Hu B., Smith A., Gelder F., De Benedetti A. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int. J. Cancer 1995, 64:27-31.
24. Li B.D., McDonald J.C., Nassar R., De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann. Surg. 1998, 227:756. 761-763.
25. Braunstein S., Karpisheva K., Pola C., et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cells 2007, 28:501-512.
26. Rojo F., Najera L., Lirola J., et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 2007, 13:81-89.
27. DeFatta R.J., Turbat-Herrera E.A., Li B.D., Anderson W., De Benedetti A. Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. Int. J. Cancer 1999, 80:516-522.
28. Oridate N., Kim H.J., Xu X., Lotan R. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol. Ther. 2005, 4:318-323.
29. Melo S.A., Ropero S., Moutinho C., et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 2009, 41:365-370.
30. Moeller B.J., Dreher M.R., Rabbani Z.N., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8:99-110.
31. Zhang X., Kon T., Wang H., et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004, 64:8139-8142.
32. Li B.D., Liu L., Dawson M., De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997, 79:2385-2390.
33. Shi M., Guo X.T., Shu M.G., Chen F.L., Li L.W. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers. Med. Hypotheses 2007, 69:33-35.
34. Zhang J., Cao J., Weng Q., et al. Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) by tirapazamine is dependent on eIF2alpha phosphorylation rather than the mTORC1/4E-BP1 pathway. PLoS ONE 2010, 5:e13910.
35. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
36. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004, 5:405-406.
37. Fuks Z., Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005, 8:89-91.
38. Moeller B.J., Dewhirst M.W. HIF-1 and tumour radiosensitivity. Br. J. Cancer 2006, 95:1-5.
39. Tian S., Li X.L., Shi M., Yao Y.Q., Li L.W., Xin X.Y. Enhance tumor radiosensitivity by intracellular delivery of eukaryotic translation initiation factor 4E binding proteins. Med. Hypotheses 2011, 76:246-248.
40. Harada H., Itasaka S., Kizaka-Kondoh S., et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 2009, 284:5332-5342.